tbuckley/cabot-search huggingface dataset:
Effects of Vitamin D on Cardiac Function in Patients With Chronic HF
Authors: Klaus K. Witte, Rowena Byrom, John Gierula, Maria F. Paton, Haqeel A. Jamil, Judith E. Lowry, Richard G. Gillott, Sally A. Barnes, Hemant Chumun, Lorraine C. Kearney, John P. Greenwood, Sven Plein, Graham R. Law, Sue Pavitt, Julian H. Barth, Richard M. Cubbon, Mark T. Kearney
Journal: Journal of the American College of Cardiology (2016)

Patients with chronic heart failure (HF) secondary to left ventricular systolic dysfunction (LVSD) are frequently deficient in vitamin D. Low vitamin D levels are associated with a worse prognosis. The VINDICATE (VitamIN D treatIng patients with Chronic heArT failurE) study was undertaken to establish safety and efficacy of high-dose 25 (OH) vitamin D3 (cholecalciferol) supplementation in patients with chronic HF due to LVSD. We enrolled 229 patients (179 men) with chronic HF due to LVSD and vitamin D deficiency (cholecalciferol <50 nmol/l [<20 ng/ml]). Participants were allocated to 1 year of vitamin D3 supplementation (4,000 IU [100 μg] daily) or matching non−calcium-based placebo. The primary endpoint was change in 6-minute walk distance between baseline and 12 months. Secondary endpoints included change in LV ejection fraction at 1 year, and safety measures of renal function and serum calcium concentration assessed every 3 months. One year of high-dose vitamin D3 supplementation did not improve 6-min walk distance at 1 year, but was associated with a significant improvement in cardiac function (LV ejection fraction +6.07% [95% confidence interval (CI): 3.20 to 8.95; p < 0.0001]); and a reversal of LV remodeling (LV end diastolic diameter -2.49 mm [95% CI: -4.09 to -0.90; p = 0.002] and LV end systolic diameter -2.09 mm [95% CI: -4.11 to -0.06 p = 0.043]). One year of 100 μg daily vitamin D3 supplementation does not improve 6-min walk distance but has beneficial effects on LV structure and function in patients on contemporary optimal medical therapy. Further studies are necessary to determine whether these translate to improvements in outcomes. (VitamIN D Treating patIents With Chronic heArT failurE [VINDICATE]; NCT01619891)
Case 1-1990
Authors: Harrison W. Farber, Eugene J. Mark
Journal: New England Journal of Medicine (1990)

Presentation of CaseA 29-year-old man was admitted to the hospital for the fourth time because of an increasing cough and fever.There was a 10-year history of bisexual activity, with treatment in the past for primary syphilis, gonorrhea, and oral candidiasis. The patient's sexual partners included one man with Kaposi's sarcoma and a Haitian man. Chronic cervical and inguinal lymphadenopathy developed eight years before entry. Twenty-two months before admission a serologic test for human immunodeficiency virus (HIV) antibodies was positive. Nineteen months before entry the patient was first admitted to this hospital because of dyspnea, dry cough, fever, and . . .
Clostridium perfringens liver abscess complicated by bacteremia
Authors: Charles Rives, Dhara Chaudhari, James Swenson, Chakradhar Reddy, Mark Young
Journal: Endoscopy (2015)

A 63-year-old man had previously undergone resection for stage III colon cancer. Liver metastasis had resolved with palliative chemotherapy. The patient was now admitted because of weight loss, obstructive jaundice, and intrahepatic and extrahepatic biliary dilatation due to extrinsic compression of the biliary tree at the porta hepatis.
Therapeutic options in peripheral T cell lymphoma
Authors: Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li
Journal: Journal of Hematology & Oncology (2016)

Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), the majority of patients relapse rapidly; the current 5-year overall survival rates are only 10–30 %. Novel targeted therapies and combination chemotherapies are required for the treatment of patients with PTCL. In recent years, some retrospective and prospective studies have been performed concerning PTCL. Consequently, a number of novel agents and their relevant combination therapies have been identified, including histone deacetylase inhibitors, immunoconjugates, antifolates, monoclonal antibodies, immunomodulatory agents, nucleoside analogs, proteasome inhibitors, kinase inhibitors, bendamustine, l-asparaginase, and other targeted agents. It is hoped that these innovative approaches will finally improve outcomes in patients with PTCL. This review summarizes the currently available approaches for the treatment of PTCL with an emphasis on potential new agents, including the role of stem cell transplantation.
P139 Investigating the profile of physical activity in COPD patients 7 days post discharge from a respiratory-related admission. Does brief advice have an effect?
Authors: P Kanabar, V Warrington, L Houchen-Wolloff, S Singh
Journal: Thorax (2015)

<h3>Introduction and objectives</h3> There is a relationship between Physical Activity (PA) and both readmissions and mortality.<sup>1</sup> PA in COPD in the immediate period following hospital admission and discharge has not received much attention. This study aimed to investigate the profile of PA in the 7 days following discharge from a respiratory-related admission. Additionally, we explored whether brief PA advice (given as part of a self-management (SM) manual) would improve the rate of recovery, compared to usual care. <h3>Methods</h3> The study was a Randomised Controlled Trial. Those randomised to UC were discharged with standard treatment and follow-upon addition, those allocated to the SM group received brief advice PA advice in the form of a SM manual (SPACE FOR COPD). All patients wore the ‘Sensewear’ armband (SWA) monitor for 7 days post-discharge for 12 waking hours/day. Outcomes collected were: Total Energy Expenditure (TEE), Steps, Physical Activity Level (PAL) and time spent in light, moderate and vigorous activity. <h3>Results</h3> Activity data was collected on 25 patients with COPD, UC = 10, SM = 15. Mean (SD) Age-67.7(7.2) years, FEV-1.01(0.43) L, MRC grade-3.8(1. X), 14 Females, 11 Males. Figure 1 shows the serial measures of steps over 7 days. There were no significant differences in physical activity at baseline between the groups. There was little fluctuation in steps over 7 days and the change was not significant from Day 1–Day 7, within in each group. Furthermore, there was no significant difference between the groups. This was the same for all of the other activity monitor data. <h3>Conclusion</h3> We found there was no improvement in steps in the 7 days post-discharge, despite PA advice given in the SM group. It may be that the advice was too brief or that 7 days was not long enough to witness an effect. Further research is required to investigate the effects of an exacerbation and SM interventions on PA; capturing PA data prior to, during and after an admission would be of value. <h3>Reference</h3> 1 Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review.<i> Respir Res</i>. 2005;<b>6</b>:54
Variation of the Systolic Murmur of Complete Heart Block
Authors: Morton E. Tavel
Journal: New England Journal of Medicine (1966)

COMPLETE heart block, with slow, regular ventricular beats, usually gives rise to a systolic murmur.1 2 3 4 Generally, this murmur is thought to result from the large stroke volume, which produces rapid ejection of blood passing through the semilunar valves; hence, one would classify it as an "ejection murmur."5 Long ago, Clarac and Pezzi4 described beat-to-beat changes in the intensity of the systolic murmur of complete heart block, and they attributed these fluctuations to varying degrees of insufficiency of the atrioventricular valves. They regarded the insufficiency as dependent to a great extent upon the changing position of the valve leaflets at the . . .
Diagnostic Value of Intravenous Cholangiography during Acute Cholecystitis and Acute Pancreatitis
Authors: Henry C. Johnson, B. Donald Minor, Jack A. Thompson, H. Stephen Weens
Journal: New England Journal of Medicine (1959)

INTRAVENOUS cholangiography with iodipamide sodium was introduced in clinical medicine in 1953 as a method for rapid high contrast visualization of the biliary ducts and gall bladder.1 An abundant literature is now available concerning the merits of this procedure in the study of a variety of chronic biliary-tract disorders. Only a few reports, however, have emphasized the possible value of utilizing intravenous cholangiography in the evaluation of the patient with an acute abdominal illness.2 3 4 During the past three years at Grady Memorial Hospital intravenous cholangiography has been performed as an emergency procedure in an unselected group of patients who were . . .
Human Bladder Carcinoma: Characterization of Two New Tumor Cell Lines and Search for Tumor Viruses23
Authors: Suraiya Rasheed, Murray B. Gardner, Robert W. Rongey, Walter A. Nelson-Rees, Paul Arnstein
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Human Bladder Carcinoma: Characterization of Two New Tumor Cell Lines and Search for Tumor Viruses Get access Suraiya Rasheed, Suraiya Rasheed Search for other works by this author on: Oxford Academic PubMed Google Scholar Murray B. Gardner, Murray B. Gardner Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert W. Rongey, Robert W. Rongey Search for other works by this author on: Oxford Academic PubMed Google Scholar Walter A. Nelson-Rees, Walter A. Nelson-Rees Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul Arnstein Paul Arnstein Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 4, April 1977, Pages 881–890, https://doi.org/10.1093/jnci/58.4.881 Published: 01 April 1977 Article history Received: 06 June 1976 Accepted: 20 September 1976 Published: 01 April 1977
“Tertiary” Hyperparathyroidism and Apparent “Cure” of Vitamin-D-Resistant Rickets after Removal of an Ossifying Mesenchymal Tumor of the Pharynx
Authors: Jerrold Olefsky, Richard Kempson, Henry Jones, Gerald Reaven
Journal: New England Journal of Medicine (1972)

Original Article from The New England Journal of Medicine — "Tertiary" Hyperparathyroidism and Apparent "Cure" of Vitamin-D-Resistant Rickets after Removal of an Ossifying Mesenchymal Tumor of the Pharynx
Antivascular activity of VB111 in glioblastoma xenografts.
Authors: A. J. Brenner, Y. Cohen, E. Breitbart, J. Rogge, F. J. Giles
Journal: Journal of Clinical Oncology (2010)

e13652 Background: Glioblastoma is a highly vascular tumor with marked endothelial dependence. While anti-angiogenic therapy has shown transient clinical benefit for the treatment of glioblastoma, persistent vascularization is seen with a normalization of blood vessels within the tumor. VB-111 is a dual-action, anti-angiogenic and vascular disrupting agent (VDA) for cancer treatment. VB-111 is aimed to specifically destroy existing angiogenic blood vessels in a potentially safe and efficient manner. VB-111 consists of a replication incompetent adenovirus together with an endothelial angiogenic-specific promoter and a pro-apoptotic Fas Chimera c transgene. We hypothesized that VB-111 would have significant activity in glioblastoma. Methods: Intracranial xenografts were established in nude rats with a luciferase expressing U87 glioma cell line. Rats were treated intravenously with a single dose of VB-111 at 1011 viral particles or placebo at 21 days post tumor cell implantation. Tumor growth was followed by in vivo bioluminescent imaging and 7T MRI. Rats were sacrificed when moribund or when marked neurologic deficit was observed. Tumors were evaluated by standard histologic methods for vessel density and necrosis. Results: Rats bearing U87 tumors treated with a single dose of VB-111 showed a significant prolongation of median survival (39.25 days control vs. 45.8 days VB- 111), decreased median luciferase activity at all time points post treatment, and decreased median tumor size on MRI at all time points post treatment. Conclusions: Anti-angiogenic therapy with VB-111 appears to be promising for glioblastoma. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Vascular Biogenics Vacular Biogenics
<i>Pneumocystis carinii</i>Pneumonia in Infants Infected with the Human Immunodeficiency Virus with More Than 450 CD4 T Lymphocytes per Cubic Millimeter
Authors: Eugene Leibovitz, Mona Rigaud, Henry Pollack, Robert Lawrence, Sulachni Chandwani, Keith Krasinski, William Borkowsky
Journal: New England Journal of Medicine (1990)

PNEUMOCYSTIS carinii pneumonia (PCP) is the most common illness defining the presence of the acquired immunodeficiency syndrome (AIDS). It occurred in 70 percent of the pediatric patients with the human immunodeficiency virus (HIV) infection whose cases have been reported to the Centers for Disease Control.1 A child's first episode of PCP is frequently fatal; children who survive the initial attack have a mortality rate of approximately 90 percent during a second clinical episode.2 Absolute CD4-lymphocyte counts have been shown to be a clinically useful indicator of immune function in HIV-infected patients. These counts are currently used to stratify HIV-infected adults . . .
Effect of Thalamic Lesions upon Torticollis
Authors: Irving S. Cooper
Journal: New England Journal of Medicine (1964)

TORTICOLLIS is an involuntary movement disorder resulting in tonic abnormal deviation of the head and neck. It is often accompanied by hyperkinesis of the head and neck, consisting of arrhythmic clonic jerks or rhythmic tremor or both. Although the head may be abnormally deviated toward one side, the nuchal musculature of both sides is invariably involved.1 Moreover, the splenius and ribbon muscles of the neck are involved as often as the sternocleidomastoid and trapezius muscles.2 Although there has been a tendency to regard many cases of torticollis as psychopathic in origin, since patients affected "appear to be looking away from . . .
First cases of Clostridium difficile PCR ribotype 027 acquired in Austria
Authors: A Indra, S Huhulescu, S Kernbichler, HW Kuo, G Feierl, A Holler, F Skrabal, G Tucek, F Allerberger
Journal: Eurosurveillance (2008)

Binary file ES_Abstracts_Final_ECDC.txt matches
Case 21-1993
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Allan H. Ropper, Ann C. McKee
Journal: New England Journal of Medicine (1993)

Presentation of CaseA 71-year-old man was admitted to the hospital because of a rash, diffuse muscle weakness, and respiratory failure.There was a long history of insulin-dependent diabetes mellitus and alcoholism. The patient had been in stable health until two or three months before entry, when a diffuse maculopapular erythematous rash developed. It improved with prednisone therapy but flared when the dose was tapered, with the onset of difficulty in walking and arising from a chair. Twenty-six days before admission he experienced sudden right flank pain and was admitted to another hospital.On physical examination a diffuse erythematous scaling . . .
Case 17-1996
Authors: David V. Ives, R. Neal Smith
Journal: New England Journal of Medicine (1996)

Presentation of CaseA 48-year-old man with the acquired immunodeficiency syndrome (AIDS) was admitted to the hospital because of bloody diarrhea and severe abdominal pain.Two years earlier, the patient had been found to have advanced AIDS and cytomegalovirus retinitis of the left eye. During the next two years, his CD4+ cell count was less than 10 per cubic millimeter, and he received ganciclovir as prophylaxis for the right eye. He had had diarrhea for many years; repeated stool examinations during the two years before admission yielded no diagnosis. Fatigue and intermittent fever were present for six months before admission. . . .
A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Authors: Daniel Peter Petrylak, David C. Smith, Leonard Joseph Appleman, Mark T. Fleming, Arif Hussain, Robert Dreicer, A. Oliver Sartor, Neal D. Shore, Nicholas J. Vogelzang, Hagop Youssoufian, William C. Olson, Nancy Stambler, Kathleen Huang, Robert Joseph Israel
Journal: Journal of Clinical Oncology (2014)

83 Background: The abundant expression of prostate-specific membrane antigen (PSMA) on prostate cancer cells provides a rationale for antibody therapy. PSMA antibody drug conjugate (ADC) is a fully human antibody to PSMA linked to the microtubule disrupting agent monomethyl auristatin E (MMAE). It binds PSMA and is internalized and cleaved by lysosomal enzymes releasing free MMAE causing cell cycle arrest and apoptosis. We enrolled 70 patients (pts) in a phase II trial of PSMA ADC in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). Methods: Pts with progressive mCRPC following taxane and ECOG PS 0 or 1 were eligible. PSMA ADC was administered Q3 week IV for up to eight cycles. Safety, tumor response by prostate-specific antigen (PSA), circulating tumor cells (CTC), imaging, biomarkers and clinical progression were assessed. Dosing was initiated at 2.5 mg/kg and adjustment for tolerability was allowed. Results: Thirty five pts began treatment at 2.5 mg/kg. Due to neutropenia, the remaining 35 pts began at 2.3 mg/kg. All pts received prior docetaxel and abiraterone and/or enzalutamide. Forty one percent also received cabazitaxel. Adverse events (AEs) were consistent with what was seen in phase I; most common significant AEs were neutropenia (grade 4, 6.7% and 11.4% at 2.3 and 2.5 mg/kg, respectively) and peripheral neuropathy (grade 3 or higher, 6.7% (2.3) and 5.7% (2.5)). Two pts at 2.5 mg/kg died of sepsis. 43% of pts at 2.3 and 37% of pts at 2.5 had declines in CTC from 5 or more to less than 5 cells/7.5 ml blood and 57.1% (2.3) and 74.1% (2.5) had 50% or more CTC declines; 26.1% (2.3) and 16.1% (2.5) had PSA declines of 30% or more thus far. PSA and CTC responses were associated with higher PSMA expression on CTC and lower neuroendocrine (NE) markers. The CTC conversion rate (5 or more to less than 5) was approximately 80% in pts with low NE markers. Prior cabazitaxel or abiraterone and/or enzalutamide did not appear to affect response. Centralized assessments of images by RECIST of all pts are currently planned and will be presented. Conclusions: PSMA ADC at 2.3 mg/kg was generally well tolerated in pts with progressive mCRPC previously treated with taxane. Anti-tumor activity, CTC and PSA reductions were observed at 2.3 and 2.5 mg/kg. Updated safety, tumor response and radiographic assessments from the full cohorts of 2.3 and 2.5 mg/kg will be presented. Testing in taxane naïve pts is also ongoing. Clinical trial information: NCT01695044.
Megaloblastic Crisis in Paroxysmal Nocturnal Hemoglobinuria
Authors: George J. Pavlic, Bertha A. Bouroncle
Journal: New England Journal of Medicine (1965)

PAROXYSMAL nocturnal hemoglobinuria is a rarely recognized cause of hemolytic anemia. Although the exact etiology remains obscure, the erythrocytes develop a defect that sensitizes them to increased destruction in an acid medium.1 , 2 It is becoming more evident that the disease must be considered in the differential diagnoses of many illnesses because of its variable clinical manifestations.3 In the case reported below, an "aplastic-megaloblastic" crisis was accompanied by hemolysis. The development of a megaloblastic maturation arrest in the course of chronic hemolytic anemias, both congenital and acquired, is being recognized more frequently,4 5 6 7 and has recently been summarized by Lindenbaum and Klipstein. . . .
Adverse Cytogenetic Abnormalities At Diagnosis Are The Most Important Predictor Of Relapse Post T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Advanced Myelodysplastic Syndrome (MDS)
Authors: Roni Tamari, Ann A. Jakubowski, Esperanza B. Papadopoulos, Sergio A Giralt, Jenna D Goldberg, Doris M Ponce, Craig S. Sauter, Patrick Hilden, Sean Devlin, James W. Young, Hugo Castro-Malaspina
Journal: Blood (2013)
Pathologic Anatomy of Pseudobranch Tumors in Pacific Cod, Gadus macrocephalus2
Authors: C. E. Alpers, B. B. Cain, M. Myers, S. R. Wellings, M. Poore, J. Bagshaw, C. J. Dawe
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Pathologic Anatomy of Pseudobranch Tumors in Pacific Cod, Gadus macrocephalus Get access C. E. Alpers, C. E. Alpers Search for other works by this author on: Oxford Academic PubMed Google Scholar B. B. Cain, B. B. Cain Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Myers, M. Myers Search for other works by this author on: Oxford Academic PubMed Google Scholar S. R. Wellings, S. R. Wellings Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Poore, M. Poore Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Bagshaw, J. Bagshaw Search for other works by this author on: Oxford Academic PubMed Google Scholar C. J. Dawe C. J. Dawe Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 2, August 1977, Pages 377–398, https://doi.org/10.1093/jnci/59.2.377 Published: 01 August 1977 Article history Received: 27 September 1976 Accepted: 19 February 1977 Published: 01 August 1977
Studies on Metastases. I. Role of Sensitization and Immunosuppression
Authors: M Seshadri, T B Poduval, K Sundaram
Journal: JNCI Journal of the National Cancer Institute (1979)

A normally nonmetastatic tumor metastasized to the regional axillary lymph nodes following severe immunosuppression ofinbred Swiss mice. The extent of metastasis was dependent on the severity of lymphocyte depletion and the initial number of tumor cells injected. Sensitization of the host to the tumor was important in prevention of metastasis: Metastasis was induced only if the immunosuppressive treatment occurred within 3 days of tumor inoculation. Antitumor immunity was adoptively transferred by the splenocytes from animals given immunosuppressive treatment with X-rays or hydrocortisone acetate on day 14. Though spleen cells from animals given both immunosuppressants did not have this property, that no metastasis was observed even in doubly immunosuppressed mice indicated sensitization to tumor cells. Lymphocyte number was important also: injection of splenocytes from normal to tumor-bearing animals significantly reduced the occurrence of metastases
Physicians’ Knowledge About FDA Approval Standards and Perceptions of the “Breakthrough Therapy” Designation
Authors: Aaron S. Kesselheim, Steven Woloshin, Wesley Eddings, Jessica M. Franklin, Kathryn M. Ross, Lisa M. Schwartz
Journal: JAMA (2016)

This survey study examines how well physicians understand the US Food and Drug Administration’s (FDA’s) statutory definition of a “breakthrough” therapy, and whether the term breakthrough affects their perceptions of a drug’s efficacy.
In experimental chronic kidney disease or cancer, parathyroid hormone is a novel mediator of cachexia
Authors: Christina M. Wyatt, William E. Mitch
Journal: Kidney International (2016)

Hyperparathyroidism plays a central role in the disordered bone mineral metabolism of chronic kidney disease, and has been associated with increased cardiovascular morbidity and mortality in that setting. A recent study suggests a novel role for parathyroid hormone and its receptor in muscle wasting and cachexia occurring in advanced chronic kidney disease.